In adults with active psoriatic arthritis, continued treatment with guselkumab was associated with skin clearance and joint symptom improvement through 2 years, according to long-term data from the phase 3 DISCOVER-2 study.<\/p>\n
In DISCOVER-2 (ClinicalTrials.gov:NCT03158285), patients with active psoriatic arthritis (N=739) were randomly assigned to guselkumab 100mg every 4 or every 8 weeks for 2 years, or to placebo with crossover to guselkumab every 4 weeks at week 24 through 2 years. The study aimed to evaluate multiple clinical outcomes including joint and skin symptoms and radiographic progression in patients with psoriatic arthritis.<\/p>\n
Results at week 100 showed that 76% of patients receiving guselkumab every 4 weeks and 74% of patients receiving treatment every 8 weeks achieved at least 20 percent improvement in the American College of Rheumatology (ACR20) response criteria. Findings also revealed that 56% and 55% of patients treated with guselkumab every 4 weeks and 8 weeks, respectively, achieved at least 50 percent improvement in ACR score. Moreover, low rates of radiographic progression of joint damage were observed in patients receiving guselkumabfrom week 52-100.<\/p>\n
Among patients who had clinically meaningful skin involvement at baseline, 59% and 53% of patients treated with guselkumab every 4 weeks and 8 weeks, respectively, achieved complete skin clearance (Psoriasis Area Severity Index [PASI] 100). Additionally, 62% and 55% of patients receiving guselkumab every 4 and 8 weeks, respectively, achieved complete skin clearance as measured by the Investigator Global Assessment (IGA) score of 0.<\/p>\n
The safety of guselkumab in patients with active psoriatic arthritis through 2 years was found to be comparable to safety at 6 months and 1 year and was consistent with the safety profile seen in patients with moderate to severe plaque psoriasis. No new safety signals were observed through week 112.<\/p>\n
Full data from the DISCOVER-2 trial will be presented during the Innovations in Dermatology: Virtual Spring Conference, March 16 to 20, 2021.<\/p>\n
Guselkumab, an interleukin-23 antagonist, is marketed under the trade nameTremfyaand is approved for the treatment of psoriatic arthritis and moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.<\/p>\n
New phase 3 data show first-in-class Tremfya(guselkumab) achieved complete skin clearance and favorable joint efficacy in adult patients with active psoriatic arthritis (PsA) through two years. [press release]. Spring House, PA: Janssen; March 16, 2021.<\/p>\n
This article originally appeared on MPR<\/p>\n
<\/p>\n
See the rest here: In adults with active psoriatic arthritis, continued treatment with guselkumab was associated with skin clearance and joint symptom improvement through 2 years, according to long-term data from the phase 3 DISCOVER-2 study. In DISCOVER-2 (ClinicalTrials.gov:NCT03158285), patients with active psoriatic arthritis (N=739) were randomly assigned to guselkumab 100mg every 4 or every 8 weeks for 2 years, or to placebo with crossover to guselkumab every 4 weeks at week 24 through 2 years. Continue reading
\nGuselkumab Benefits Observed Through 2 Years in Psoriatic Arthritis Trial - Dermatology Advisor<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"